import time
from dataclasses import dataclass

class RegulatoryDrafter:
    """
    Anthropic Health Stack Agent: Regulatory Drafter
    
    Demonstrates:
    1. Long Context Handling (Mocked).
    2. Chain-of-Thought transparency (<thinking> blocks).
    3. Precise, citation-based generation.
    """
    
    def __init__(self, model: str = "claude-3-5-sonnet-20241022"):
        self.model = model

    def draft_submission(self, clinical_data: str, fda_guidance: str) -> str:
        """
        Drafts a regulatory submission section based on data and guidance.
        """
        print(f"--- RegulatoryDrafter: Processing with {self.model} ---")
        print(f"Input: Clinical Data ({len(clinical_data)} chars) + Guidance ({len(fda_guidance)} chars)")
        
        # SIMULATING ANTHROPIC'S "THINKING" BLOCK
        # Anthropic models excel at showing their reasoning inside XML tags before answering.
        
        print("\n>> Claude is thinking...")
        time.sleep(1.0)
        
        thinking_process = """
<thinking>
1.  **Analyze the Request**: The user wants a submission section justifying the exclusion of pediatric patients.
2.  **Review Guidance**: The provided FDA guidance (Section 4.2) states that pediatric waivers are granted if the disease does not exist in children.
3.  **Review Data**: The clinical data shows the target indication is "Age-related Macular Degeneration" (AMD), which typically affects patients > 50.
4.  **Formulate Argument**:
    *   Premise 1: Disease biology is age-dependent.
    *   Premise 2: No pediatric population exists for this indication.
    *   Conclusion: Request full waiver per 21 CFR 314.55(c)(2).
5.  **Drafting Strategy**: Use formal regulatory tone. Cite specific CFR codes.
</thinking>
"""
        print(thinking_process)
        
        # THE FINAL OUTPUT
        draft = """
**Draft Submission: Pediatric Assessment Waiver Request**

Pursuant to 21 CFR 314.55(c)(2), the Sponsor requests a full waiver of the requirement to submit data on the assessment of the safety and effectiveness of [Drug X] in pediatric subpopulations.

**Rationale:**
The indication sought, Age-related Macular Degeneration (AMD), is an adult-onset condition that does not occur in the pediatric population. As noted in the provided Clinical Overview (Section 2.1), the youngest patient enrolled in Phase 3 trials was 58 years of age.

Therefore, studies in pediatric patients are impossible or highly impracticable because the number of such patients is so small or geographically dispersed.
"""
        return draft

if __name__ == "__main__":
    agent = RegulatoryDrafter()
    
    # Mock Inputs
    data_snippet = "Study 101 enrolled 500 patients. Mean age 72. Diagnosis: Wet AMD."
    guidance_snippet = "FDA Guidance for Industry: Pediatric Study Plans..."
    
    result = agent.draft_submission(data_snippet, guidance_snippet)
    print("\n>> Final Output:")
    print(result)

